Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (2245)	1/11/2018 12:37:34 AM
From: Miljenko Zuanic	Respond to of 3559

Last time BI Ridgefield facility were inspected by FDA was 2-2017, no 483 letter issued. Shanghai facility was never inspected/approved by FDA. Because BGNE will (or would) have first approval in China, BI production will be for that market. For US/EU, I am sure CELG will rent more production capacity, most likely from Lonza. Anyway, point is that BGNE will probably be 4-th with anti-PD1 in US, and will be direct competitor. So far appears with decent activity.